Titan Medical Appoints Medtech Industry Veteran Domenic Serafino to Its Board of Directors
June 28 2018 - 7:15AM
Titan Medical Inc. (“Titan” or the “Company”)
(TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the
design, development and commercialization of a robotic surgical
system for application in minimally invasive surgery (“MIS”),
announces the appointment of Domenic Serafino to its board of
directors, effective June 28. Mr. Serafino has held executive
positions with various Canadian medical technology companies for
more than 20 years. His appointment increases the size of
Titan’s board to six directors.
“We are delighted to welcome Dom to our board of
directors,” said John E. Barker, Director and Chairman of Titan
Medical. “His significant experience leading sales, marketing and
operations, along with in-depth knowledge of the regulatory paths
at several very successful companies will be of benefit to Titan as
we complete development of our SPORT single-port robotic surgery
system and prepare regulatory submissions during the next two
years. In addition, we welcome Domenic’s experience with
Nasdaq-listed companies.”
Mr. Serafino is Chairman and Chief Executive
Officer of Venus Concept Ltd., an aesthetic medical device company
he founded in 2010. Mr. Serafino built the company to
approximately $120 million in annual revenue with sales in more
than 60 countries, and 450 employees in 27 markets.
Previously he was with aesthetic medical laser company Syneron, now
Candela Syneron, as president for North America, and was
instrumental in taking the company public on Nasdaq in August 2004.
During his five-year tenure, the company’s revenue increased from
$0 to approximately $65 million, with a market value of
approximately $1.3 billion. Prior to Syneron Mr. Serafino was
a partner, president and chief operating officer of Canada’s
largest laser distribution company, Sigmacon Group, from 1995 to
2001.
Commenting on his appointment to Titan’s board,
Mr. Serafino said, “I am pleased to be joining Titan Medical’s
board at such a pivotal moment in the company’s development as it
prepares to enter the rapidly-growing robotic surgery market.
With its stock now listed on Nasdaq and my experience with public
medical technology companies, I believe I can have a positive
impact on the company’s development and progress.”
Mr. Serafino serves as Chairman of the Board of
Directors of Venus Concepts and also sits on the Board of Directors
of Scientus Pharma, a privately-held biopharmaceutical company
based in Toronto. He holds a general business administration
degree from Centennial College of Applied Arts and Technology in
Toronto.
About Titan Medical Inc.
Titan Medical Inc. is focused on research and
development through to the planned commercialization of
computer-assisted robotic surgical technologies for application in
minimally invasive surgery. The Company is developing the SPORT
Surgical System, a single-port robotic surgical system. The SPORT
Surgical System is comprised of a surgeon-controlled patient cart
that includes a 3D high-definition vision system and
multi-articulating instruments for performing MIS procedures, and a
surgeon workstation that provides an advanced ergonomic interface
to the patient cart and a 3D endoscopic view inside the patient’s
body. Titan intends to initially pursue focused surgical
indications for the SPORT Surgical System, which may include one or
more of gynecologic, urologic, colorectal or general abdominal
procedures.
For more information, please visit the Company’s
website at www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking
statements” which reflect the current expectations of management of
the Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Information Form dated March 31, 2018 (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward looking
statements prove incorrect, actual results, performance or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully, and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the news release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements.
Contacts:
LHA Investor Relations Kim Sutton Golodetz(212)
838-3777kgolodetz@lhai.com orBruce Voss(310)
691-7100bvoss@lhai.com
Titan Medical (TSX:TMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Medical (TSX:TMD)
Historical Stock Chart
From Apr 2023 to Apr 2024